Radiopharmaceuticals are on the rise worldwide. Join key players to explore how Europe is driving progress in this exciting field – and what it means for the future of cancer care around the world.

• Demonstrating significant progression-free survival benefits for mCRPC patients treated with Pluvicto
• The success of Pluvicto in improving progression-free survival compared to standard care
• New challenges and opportunities in RLT: new targets, combinations